PharmaCyte Biotech, Inc.
PharmaCyte Biotech, Inc.
Your view on PMCB
Overview
What the company does, where it operates, and who runs it.
About PharmaCyte Biotech, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Joshua N. Silverman
- Headquarters
- 3960 Howard Hughes Parkway, Las Vegas, NV, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Joshua N. Silverman
- Headquarters
- 3960 Howard Hughes Parkway, Las Vegas, NV, US
PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States.
Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes.
The company is developing therapies for pancreatic and other solid cancerous tumors; a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes, which include encapsulated genetically modified insulin-producing cells; and therapies for cancer based on the constituents of the cannabis plant.
It has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes; and the University of Northern Colorado to develop methods for the identification, separation, and quantification of constituents of cannabis.
The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for PharmaCyte Biotech, Inc., and the rating behind it. PMCB last traded at $0.45; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for PharmaCyte Biotech, Inc.. Starting points for PharmaCyte Biotech, Inc.: EPS -$2.02, beta 0.66 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for PharmaCyte Biotech, Inc.. PharmaCyte Biotech, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for PharmaCyte Biotech, Inc.. Trailing twelve-month EPS for PharmaCyte Biotech, Inc. stands at -$2.02. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for PharmaCyte Biotech, Inc.. PharmaCyte Biotech, Inc. has reported as a listed company since 2013. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
PharmaCyte Biotech, Inc. valued side by side against its closest peers. PharmaCyte Biotech, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold PharmaCyte Biotech, Inc., and how their positions are changing. At a $4.8M market value, institutional positions materially move PharmaCyte Biotech, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by PharmaCyte Biotech, Inc. executives and directors. Shares of PharmaCyte Biotech, Inc. have traded between $0.70 and $1.90 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming PharmaCyte Biotech, Inc.. PharmaCyte Biotech, Inc. is a $4.8M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming PharmaCyte Biotech, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for PharmaCyte Biotech, Inc.. Coverage tracks PharmaCyte Biotech, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.